YLYanhui Liu

Yanhui Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanhui Liu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Miscarriage Risk Prediction for Women With Polycystic Ovary Syndrome Who Achieve Clinical Pregnancy After Fresh Embryo Transfer: Multicenter Development, Geographic External Validation, and Prospective Temporal Validation Study

    by Juncheng Tong, Yingying Zhang, Yanhui Liu, Lifang Liu, Xiaoteng Shang, Fanggui Wu, Haoxuan Guo, Sibo Zhang, Kai Zhao, Aifa Tang, et al.

    Background: Women with polycystic ovary syndrome (PCOS) who achieve clinical pregnancy following fresh in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) carry an elevated miscarriage risk. However, individualized risk stratification after clinical pregnancy confirmation but before outcome determination remains challenging in clinical practice. Objective: This study aimed to develop, externally and prospectively validate over time, and interpret a machine learning–based risk stratification model for women with PCOS who had achieved a confirmed clinical pregnancy after fresh IVF/ICSI. Methods: This multicenter study included 8911 clinical pregnancy IVF/ICSI cycles across development (n=7241; miscarriages: n=973), external validation (n=1170; miscarriages: n=146), and prospective temporal validation (n=500; miscarriages: n=62) cohorts. Prespecified predictors contained no observed missing values; training-fold median imputation was kept only as a leakage-safe fallback. A total of 13 candidate machine learning and traditional statistical algorithms were compared internally using repeated stratified 5-fold cross-validation (5 repeats) within the development cohort; preprocessing and hyperparameter tuning were performed exclusively in training folds. A prelocked Extreme Gradient Boosting (XGBoost) model was carried forward unchanged for external and prospective temporal validation. Cross-fitted logistic recalibration of averaged XGBoost out-of-fold probabilities was evaluated as a secondary development-sample diagnostic analysis. Model performance encompassed discrimination, precision-recall, calibration, threshold-based metrics, decision curve analysis, risk stratification, and Shapley additive explanations–based interpretability. Results: Miscarriage rates were 13.4% (973/7241), 12.5% (146/1170), and 12.4% (62/500) for the development, external validation, and prospective temporal validation cohorts, respectively. In repeated cross-validation, XGBoost (area under the receiver operating characteristic curve [AUC] 0.885, 95% CI 0.874-0.896) and LightGBM (AUC 0.882, 95% CI 0.871-0.893) showed comparable discrimination; the paired XGBoost-LightGBM DeLong test was not significant (Holm-adjusted P=.07). Raw XGBoost out-of-fold probabilities overestimated absolute risk (mean predicted risk 30.3% vs observed risk 13.4%); cross-fitted recalibration within the development cohort improved calibration but was not propagated to validation cohorts. The locked XGBoost model achieved AUCs of 0.787 (95% CI 0.748-0.827; Brier score 0.099) in external validation and 0.763 (95% CI 0.709-0.816; Brier score 0.104) in prospective temporal validation, showing cross-cohort performance attenuation. Risk-quartile stratification using fixed development-cohort cutoffs showed consistent event enrichment across validation cohorts, but positive predictive values remained modest. Shapley additive explanations analysis identified anti-Müllerian hormone, endometrial thickness on the day of human chorionic gonadotropin administration, and basal luteinizing hormone as leading predictors. Conclusions: The locked XGBoost model using routine preoutcome variables may support miscarriage risk stratification and counseling for women with PCOS with clinical pregnancy after fresh IVF/ICSI. Given cross-cohort discrimination loss and calibration drift, it should serve only as a risk-ranking tool, not for diagnosis or treatment selection. Local calibration monitoring is mandatory before any real-world clinical deployment.

  • Open Access

    Miscarriage Risk Prediction for Women With Polycystic Ovary Syndrome Who Achieve Clinical Pregnancy After Fresh Embryo Transfer: Multicenter Development, Geographic External Validation, and Prospective Temporal Validation Study (Preprint)

    by Juncheng Tong, Yingying Zhang, Yanhui Liu, Lifang Liu, Xiaoteng Shang, Fanggui Wu, Haoxuan Guo, Sibo Zhang, Kai Zhao, Aifa Tang, et al.

    BACKGROUND Women with polycystic ovary syndrome (PCOS) who achieve clinical pregnancy following fresh in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) carry an elevated miscarriage risk. However, individualized risk stratification after clinical pregnancy confirmation but before outcome determination remains challenging in clinical practice. OBJECTIVE This study aimed to develop, externally and prospectively validate over time, and interpret a machine learning–based risk stratification model for women with PCOS who had achieved a confirmed clinical pregnancy after fresh IVF/ICSI. METHODS This multicenter study included 8911 clinical pregnancy IVF/ICSI cycles across development (n=7241; miscarriages: n=973), external validation (n=1170; miscarriages: n=146), and prospective temporal validation (n=500; miscarriages: n=62) cohorts. Prespecified predictors contained no observed missing values; training-fold median imputation was kept only as a leakage-safe fallback. A total of 13 candidate machine learning and traditional statistical algorithms were compared internally using repeated stratified 5-fold cross-validation (5 repeats) within the development cohort; preprocessing and hyperparameter tuning were performed exclusively in training folds. A prelocked Extreme Gradient Boosting (XGBoost) model was carried forward unchanged for external and prospective temporal validation. Cross-fitted logistic recalibration of averaged XGBoost out-of-fold probabilities was evaluated as a secondary development-sample diagnostic analysis. Model performance encompassed discrimination, precision-recall, calibration, threshold-based metrics, decision curve analysis, risk stratification, and Shapley additive explanations–based interpretability. RESULTS Miscarriage rates were 13.4% (973/7241), 12.5% (146/1170), and 12.4% (62/500) for the development, external validation, and prospective temporal validation cohorts, respectively. In repeated cross-validation, XGBoost (area under the receiver operating characteristic curve [AUC] 0.885, 95% CI 0.874-0.896) and LightGBM (AUC 0.882, 95% CI 0.871-0.893) showed comparable discrimination; the paired XGBoost-LightGBM DeLong test was not significant (Holm-adjusted P=.07). Raw XGBoost out-of-fold probabilities overestimated absolute risk (mean predicted risk 30.3% vs observed risk 13.4%); cross-fitted recalibration within the development cohort improved calibration but was not propagated to validation cohorts. The locked XGBoost model achieved AUCs of 0.787 (95% CI 0.748-0.827; Brier score 0.099) in external validation and 0.763 (95% CI 0.709-0.816; Brier score 0.104) in prospective temporal validation, showing cross-cohort performance attenuation. Risk-quartile stratification using fixed development-cohort cutoffs showed consistent event enrichment across validation cohorts, but positive predictive values remained modest. Shapley additive explanations analysis identified anti-Müllerian hormone, endometrial thickness on the day of human chorionic gonadotropin administration, and basal luteinizing hormone as leading predictors. CONCLUSIONS The locked XGBoost model using routine preoutcome variables may support miscarriage risk stratification and counseling for women with PCOS with clinical pregnancy after fresh IVF/ICSI. Given cross-cohort discrimination loss and calibration drift, it should serve only as a risk-ranking tool, not for diagnosis or treatment selection. Local calibration monitoring is mandatory before any real-world clinical deployment.

  • Open Access

    Integrated Prediction System for Individualized Ovarian Stimulation and Ovarian Hyperstimulation Syndrome Prevention: Algorithm Development and Validation

    by Jingjing Chen, Jianjuan Zhao, Huiyu Qiu, Yanhui Liu, Yunqi Zhang, Qicheng Sun, Yan Yi, Hongying Tang, Jing Zhao, Bin Xu, et al.

    Background: Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). Objective: This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. Methods: This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. Results: For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). Conclusions: This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.


  • Open Access

    Integrated Prediction System for Individualized Ovarian Stimulation and Ovarian Hyperstimulation Syndrome Prevention: Algorithm Development and Validation (Preprint)

    by Jingjing Chen, Jianjuan Zhao, Huiyu Qiu, Yanhui Liu, Yunqi Zhang, Qicheng Sun, Yan Yi, Hongying Tang, Jing Zhao, Bin Xu, et al.

    BACKGROUND Accurately predicting ovarian response and determining the optimal starting dose of follicle-stimulating hormone (FSH) remain critical yet challenging for effective ovarian stimulation. Currently, there is a lack of a comprehensive model capable of simultaneously forecasting the number of oocytes retrieved (NOR) and assessing the risk of early-onset moderate-to-severe ovarian hyperstimulation syndrome (OHSS). OBJECTIVE This study aimed to establish an integrated mode capable of forecasting the NOR and assessing the risk of early-onset moderate-to-severe OHSS across varying starting doses of FSH. METHODS This prognostic study included patients undergoing their first ovarian stimulation cycles at 2 independent in vitro fertilization clinics. Automated classifiers were used for variable selection. Machine learning models (11 for NOR and 11 for OHSS) were developed and validated using internal (n=6401) and external (n=3805) datasets. Shapley additive explanation was applied for variable interpretation. The best-performing models were incorporated into a web-based prediction tool. RESULTS For NOR prediction, 17 variables were selected, with the gradient boosting regressor achieving the highest performance (internal dataset: R2=0.7978; external dataset: R2=0.7924). For OHSS prediction, 19 variables were identified, and the LightGBM model demonstrated superior performance (internal dataset: area under the receiver operating characteristic curve=0.7588; external dataset: area under the receiver operating characteristic curve=0.7287). Shapley additive explanation analysis highlighted the FSH starting dose to BMI ratio and baseline antral follicle count as key predictors for NOR and OHSS, respectively. Dose-response curves were generated to visualize predicted outcomes with varying FSH starting doses. The models were implemented in a user-friendly, research-oriented online prototype, individualized ovarian stimulation guide (InOvaSGuide). CONCLUSIONS This study introduces an integrated framework for predicting NOR and early-onset moderate-to-severe OHSS risk across different FSH doses. Future prospective evaluation is needed before clinical implementation.